close
This ad will auto close in 10 seconds
Bayer sets $66 billion deal for Monsanto after lengthy pursuit

Bayer sets $66 billion deal for Monsanto after lengthy pursuit

German chemicals giant Bayer announced Wednesday a $66 billion deal to buy controversial US seeds and pesticides firm Monsanto, triggering immediate criticism from farmers and environmentalists.

Bayer buys Monsanto for $66 billion after months-long pursuit

Bayer buys Monsanto for $66 billion after months-long pursuit

German chemicals giant Bayer said Wednesday it had agreed to buy the controversial US seeds and pesticides firm Monsanto for $66 billion, in a deal that triggered immediate criticism from environmentalists.

Delhi-NCR's first early earthquake warning system comes up in Gurgaon

Gurgaon on Monday witnessed the NCR`s first installation of an onsite Early Earthquake Warning System at the premises of Haryana Institute of Public Administration (HIPA), Sector 18, Gurgaon.

US court rejects Glenmark's patent plea for Finacea

Drug firm Glenmark's generic skin care drug that was under patent litigation infinges patent of Bayer, a US court has ruled.

India court blocks Bayer generic drug appeal

An Indian court has rejected German drug giant Bayer`s bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

China targets Germany's Bayer in drug price probe

China is mounting a sweeping probe into foreign pharmaceutical firms, accusing some of abusing their monopoly positions to boost prices unfairly.

Bayer CropScience inks pack to sell its unit for Rs 127cr

Agro-chemical firm Bayer CropScience Friday said it has signed an agreement with Deccan Fine Chemicals to sell its Gujarat-based unit for a little over Rs 127 crore.

Bayer CropScience sells property in Maharashtra for Rs 1,250cr

Agro-chemical firm Bayer CropScience Ltd Thursday said it has sold its property at Thane in Maharashtra for Rs 1,250 crore to Agile Real Estate.

Bayer challenges Nexavar generic licence order

Drugmaker Bayer has filed an appeal against an Indian Patents Office's order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German firm's cancer drug 'Nexavar' in India, with the Intellectual Property Appellate Board.